MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -45.60M | -35.39M | -24.27M | -13.67M | -7.44M |
| Total Depreciation and Amortization | 1.30M | 32.50K | 28.10K | 22.80K | 360.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -269.70K | 1.80M | 1.67M | 1.55M | 1.15M |
| Change in Net Operating Assets | -3.90M | 8.28M | -5.32M | -2.84M | -6.42M |
| Cash from Operations | -48.47M | -25.27M | -27.89M | -14.95M | -12.34M |
| Capital Expenditure | -175.60K | -132.20K | 0.00 | -211.80K | -284.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -147.16M | 58.41M | -87.74M | -28.59M | 117.15M |
| Cash from Investing | -147.33M | 58.28M | -87.74M | -28.80M | 116.87M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 150.70K | 91.30K | 0.00 | 52.54M | 31.17M |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -100.00 | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 91.80K | 0.00 | -1.56M | -2.75M |
| Cash from Financing | 150.70K | 183.10K | 0.00 | 50.98M | 28.42M |
| Foreign Exchange rate Adjustments | 423.80K | -325.40K | -16.90K | 46.50K | 64.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -195.23M | 32.87M | -115.65M | 7.27M | 133.00M |
